Search research articles
Contact Us
Filters
Showing results (41-50 of 170) with videos related to
Page
of 17
Sort By:
Oncology Research and Treatment
|
September 25, 2023
[Therapiesteuerung in der Hämatologie und Onkologie]
C Benedikt Westphalen, Bernd J Krause, Markus Schuler, et al.
Cancer Medicine
|
July 2, 2020
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma
Xiang Zhou, Maximilian J Steinhardt, Denise Grathwohl, et al.
Journal for Immunotherapy of Cancer
|
January 11, 2025
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies
Anna Fleischer, Sophia Kurth, Johannes Duell, et al.
Clinical Nuclear Medicine
|
July 6, 2019
Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma
Constantin Lapa, Malte Kircher, Matteo Da Via, et al.
Therapeutic Advances in Hematology
|
March 5, 2026
Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms
Xiang Zhou, Julia Mersi, Christine Riedhammer, et al.
Hematological Oncology
|
November 19, 2021
Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma
Xiang Zhou, Anna Ruckdeschel, Jessica Peter, et al.
Haematologica
|
February 1, 2015
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
Leo Rasche, Johannes Duell, Inês C Castro, et al.
Frontiers in Oncology
|
February 25, 2022
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
Claudio Cerchione, Saad Z Usmani, A Keith Stewart, et al.
Blood Cancer Journal
|
March 5, 2024
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study
Zimu Gong, Godsfavour Umoru, Jorge Monge, et al.
Academic Radiology
|
November 3, 2020
Whole-Body MRI with an Ultrahigh b-Value of 2000 s/mm<sup>2</sup> Improves the Specificity of Diffusion-Weighted Imaging in Patients with Plasma Cell Dyscrasias
Anke Heidemeier, Annette Thurner, Corona Metz, et al.
Page
of 17
Search research articles
Search
Showing results (41-50 of 170) with videos related to
Sort By:
Page
of 17
Oncology Research and Treatment
|
September 25, 2023
[Therapiesteuerung in der Hämatologie und Onkologie]
C Benedikt Westphalen, Bernd J Krause, Markus Schuler, et al.
Cancer Medicine
|
July 2, 2020
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma
Xiang Zhou, Maximilian J Steinhardt, Denise Grathwohl, et al.
Journal for Immunotherapy of Cancer
|
January 11, 2025
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies
Anna Fleischer, Sophia Kurth, Johannes Duell, et al.
Clinical Nuclear Medicine
|
July 6, 2019
Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma
Constantin Lapa, Malte Kircher, Matteo Da Via, et al.
Therapeutic Advances in Hematology
|
March 5, 2026
Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms
Xiang Zhou, Julia Mersi, Christine Riedhammer, et al.
Hematological Oncology
|
November 19, 2021
Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma
Xiang Zhou, Anna Ruckdeschel, Jessica Peter, et al.
Haematologica
|
February 1, 2015
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
Leo Rasche, Johannes Duell, Inês C Castro, et al.
Frontiers in Oncology
|
February 25, 2022
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
Claudio Cerchione, Saad Z Usmani, A Keith Stewart, et al.
Blood Cancer Journal
|
March 5, 2024
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study
Zimu Gong, Godsfavour Umoru, Jorge Monge, et al.
Academic Radiology
|
November 3, 2020
Whole-Body MRI with an Ultrahigh b-Value of 2000 s/mm<sup>2</sup> Improves the Specificity of Diffusion-Weighted Imaging in Patients with Plasma Cell Dyscrasias
Anke Heidemeier, Annette Thurner, Corona Metz, et al.
Page
of 17